Salud financiera de hoja de balance de Kancera

Salud financiera controles de criterios 6/6

Kancera tiene un patrimonio de los accionistas total de SEK47.7M y una deuda total de SEK0.0, lo que sitúa su ratio deuda-patrimonio en 0%. Sus activos y pasivos totales son SEK65.6M y SEK18.0M respectivamente.

Información clave

Ratio deuda-patrimonio

kr0

Deuda

Ratio de cobertura de intereses	n/a
Efectivo	kr45.69m
Patrimonio	kr47.67m
Total pasivo	kr17.98m
Activos totales	kr65.64m

Actualizaciones recientes sobre salud financiera

Recent updates

We Think Kancera (STO:KAN) Needs To Drive Business Growth Carefully

Dec 06

Is Kancera (STO:KAN) In A Good Position To Deliver On Growth Plans?

Jul 19

Companies Like Kancera (STO:KAN) Are In A Position To Invest In Growth

Mar 08

We Think Kancera (STO:KAN) Can Afford To Drive Business Growth

Jun 29

We're Hopeful That Kancera (STO:KAN) Will Use Its Cash Wisely

Mar 08

Here's Why We're Watching Kancera's (STO:KAN) Cash Burn Situation

Aug 02

We're Not Very Worried About Kancera's (STO:KAN) Cash Burn Rate

Apr 06

Here's Why We're Not Too Worried About Kancera's (STO:KAN) Cash Burn Situation

Dec 21

Análisis de la situación financiera

Pasivos a corto plazo: Los activos a corto plazo (SEK47.6M) de KAN superan a sus pasivos a corto plazo (SEK18.0M).

Pasivo a largo plazo: KAN no tiene pasivos a largo plazo.

Historial y análisis de deuda-patrimonio

Nivel de deuda: KAN está libre de deudas.

Reducción de la deuda: KAN no tiene deuda en comparación con hace 5 años, cuando su ratio deuda-patrimonio era de 2%.

Hoja de balance

Análisis de cash runway

En el caso de las empresas que de media han sido deficitarias en el pasado, evaluamos si tienen al menos 1 año de cash runway.

Cash runway estable: KAN tiene suficiente cash runway para 10 meses según el flujo de caja libre último declarado, pero desde entonces ha obtenido capital adicional.

Pronóstico de cash runway: Se prevé que KAN disponga de suficiente cash runway para 9 meses según las estimaciones de flujo de caja libre, aunque ha obtenido desde entonces capital adicional.

Salud financiera de hoja de balance de Kancera

Salud financiera controles de criterios 6/6

Información clave

Actualizaciones recientes sobre salud financiera

We Think Kancera (STO:KAN) Needs To Drive Business Growth Carefully

Is Kancera (STO:KAN) In A Good Position To Deliver On Growth Plans?

Companies Like Kancera (STO:KAN) Are In A Position To Invest In Growth

We Think Kancera (STO:KAN) Can Afford To Drive Business Growth

We're Hopeful That Kancera (STO:KAN) Will Use Its Cash Wisely

Here's Why We're Watching Kancera's (STO:KAN) Cash Burn Situation

Recent updates

Kancera AB (publ) Reports Positive Results from the Clinical Phase I Study with KAND145 in Healthy Subjects

New major risk - Shareholder dilution

Forecast breakeven date pushed back to 2025

Kancera AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 73.011989 million.

New major risk - Financial position

New major risk - Share price stability

Kancera AB (publ) Reports Positive Top Line Results from the FRACTAL Study

We Think Kancera (STO:KAN) Needs To Drive Business Growth Carefully

Forecast breakeven date moved forward to 2024

Kancera AB (publ), Annual General Meeting, May 27, 2024

Kancera AB (publ) Receives Finnish Regulatory Agency Approval for Phase I Study of KAND145

Kancera AB (publ) Appoints Markus Jerling as Chief Medical Officer

Kancera AB (publ) to Report Q3, 2023 Results on Nov 17, 2023

New major risk - Share price stability

Kancera AB (Publ) Announces Newly Published Research Publication Confirms the Potential for Kancera's Fractalkine Blocker KAND567 in Cardiovascular Disease

Is Kancera (STO:KAN) In A Good Position To Deliver On Growth Plans?

New minor risk - Share price stability

Kancera AB (publ) Reports Dosing of First Patient in the KANDOVA Study

Kancera AB (publ) Appoints Peter Selin as New Chief Executive Officer, Effective from July 1 2023

Independent Director recently sold kr58k worth of stock

Companies Like Kancera (STO:KAN) Are In A Position To Invest In Growth

Forecast to breakeven in 2025

Kancera AB (publ) Submits Regulatory Application to the Swedish Medical Products Agency to Conduct Clinical Studies of KAND567 in Ovarian Cancer

Insufficient new directors

Kancera AB (publ) Reports New Preclinical Results Supporting Potential for Its Ror1 Inhibitor in B-Cell Malignancies

Kancera AB (publ) Reports Promising Preclinical Results from Studies of Its Fractalkine Axis Blocking Drug Candidates in B-Cell Lymphoma

Kancera AB (publ) Reports Good Progress of Recruitment in Ongoing Phase IIa Study of Kand567 in Myocardial Infarction and the Decision to Allow for Recruitment of Additional Patients

Kancera AB (publ) Reports Convincing Preclinical Results and Decision to Initiate Clinical Development of KAND567 in Ovarian Cancer

We Think Kancera (STO:KAN) Can Afford To Drive Business Growth

Insufficient new directors

We're Hopeful That Kancera (STO:KAN) Will Use Its Cash Wisely

Insufficient new directors

Here's Why We're Watching Kancera's (STO:KAN) Cash Burn Situation

First quarter 2021 earnings released: kr0.029 loss per share (vs kr0.56 loss in 1Q 2020)

Insider recently bought kr65k worth of stock

We're Not Very Worried About Kancera's (STO:KAN) Cash Burn Rate

Full year 2020 earnings released: kr0.13 loss per share (vs kr0.18 loss in FY 2019)

New 90-day low: kr1.62

Here's Why We're Not Too Worried About Kancera's (STO:KAN) Cash Burn Situation

New 90-day low: kr2.23

New 90-day low: kr2.37

Kancera AB (publ) to Report Q3, 2021 Results on Nov 19, 2021

New 90-day high: kr3.98

First half earnings released

New 90-day high - kr2.96

Oncopeptides AB (publ) (OM:ONCO) agreed to acquire Kancera's drug development facility in Solna, Sweden.

Análisis de la situación financiera

Historial y análisis de deuda-patrimonio

Hoja de balance

Análisis de cash runway

Descubre empresas con salud financiera